---
title: "Tianjin's brain-computer interface lab: a 1-billion-yuan bet on 'thinking' tech"
date: 2026-11-13
category: Brain–Computer Interface
site: NeuroAI
canonical: https://neuroai.site/a/na-brain-tianjin-haihe-lab-bci
language: en
---

# Tianjin's brain-computer interface lab: a 1-billion-yuan bet on 'thinking' tech

> How a Tianjin University-led Haihe Laboratory turned non-invasive BCI from lab demos into rehab devices, chips and a talent pipeline.

A researcher at a Tianjin lab imagines growing a "sixth finger" at the wrist, and a small wearable device on the hand closes its grip around a ball. No muscles move; the command comes from the thought alone. Around the same building, a sliver of cultured tissue sits in a dish, receiving signals and steering a tiny robot through a sandbox. Scenes like these are why one city decided to back brain-computer interface (脑机接口) with industrial-scale money.

Most Chinese BCI coverage swings between sci-fi implants and vague policy promises. The Tianjin case is different: it shows a reasonably complete chain from chips to clinics, funded and organized like an industry, not just a science project.

## The lab behind the bet

The 脑机交互与人机共融海河实验室 (Brain-Computer Interaction and Human-Machine Symbiosis Haihe Laboratory) was inaugurated on 27 March 2023, led by Tianjin University (天津大学) and anchored by its neural-engineering team. Its director is Ming Dong (明东), a Tianjin University vice president whose group has spent years on non-invasive BCI for stroke rehabilitation. It is one of Tianjin's municipal Haihe Laboratories, a model the city uses to concentrate talent and capital on frontier fields.

The lab's stated focus is non-invasive brain-computer interface (脑机接口) — reading brain signals from outside the skull rather than implanting electrodes.

## From chips to clinics

The most concrete outputs carry the "Shengong" (神工) brand. The group's earlier 神工一号 was described as the first pure-thought-controlled artificial neuro-robot for whole-limb stroke rehabilitation, cleared for clinical testing in multiple tertiary hospitals. A newer finger-worn device, the 神工—灵犀指 (Shengong-Lingxi Finger), lets a user drive assisted grip through intention, aiming to wake up impaired hand function after stroke.

The logic behind these tools is neurofeedback in a loop: the system reads the patient's movement intention from brain signals, drives an external actuator, and feeds the result back to the brain, so that repeated training can re-route motor pathways damaged by a stroke. That is a different ambition from the invasive implants grabbing headlines elsewhere — it keeps the skull intact and aims at the large, underserved population of stroke survivors rather than the smaller group of paralyzed or locked-in patients.

On the components side, the lab and its spin-offs released the 神工—神关 (Shengong-Shenguan), billed as China's first fully domestic high-performance event-related-potential instrument. It runs on the second-generation 脑语者 (BrainTalker) chip, an 8-channel, 24-bit high-precision EEG acquisition chip with independent intellectual property. Separately, the team built MetaBCI, described as China's first open-source BCI software platform, and MetaBOC, an on-chip BCI intelligent interaction system that made a 2024 domestic top-ten science-news list.

## The 1-billion-yuan engine

In May 2024 the lab launched the 脑机海河实验室基金, the first special fund aimed squarely at the BCI industry, with an initial target scale of 1 billion yuan (≈ US$140M / HK$1.1B). It was set up with the Tianjin Binhai Hi-Tech Zone, the Hexi district government and other partners, explicitly built around a "scientists + entrepreneurs + government + investors" model to pull social capital into the full BCI supply chain.

Alongside the fund, the lab formed a Beijing-Tianjin-Hebei industry alliance with roughly 40 institutions, including China Electronics (中国电子). On the talent side, Tianjin University opened China's first undergraduate BCI major direction in 2024 and added the country's first first-level disciplinary doctoral program in BCI in 2025 — an attempt to stop the field's bottleneck at the human end.

## Where it actually stands

Local coverage reports a family of about ten rehab devices already developed, more than eight medical-device registrations obtained, and some products reaching patients through medical insurance (医保). The lab also claims one of the largest BCI patent portfolios in the world. Non-invasive BCI rehab for stroke is genuinely moving from demo to deployment here, with the fund and alliance meant to keep the pipeline flowing.

## Why a non-invasive path matters

China's stroke burden is enormous, and rehab capacity is thin relative to demand. A non-invasive, eventually portable system that clinics or even community rehab centers can run has a very different addressable market from a surgical implant. The lab has signaled the next step is exactly that — smaller, more portable devices that lower-tier rehab institutions, and eventually homes, could use. If that transition works, the bottleneck shifts from "can we build it" to "can we prove it helps and pay for it."

That is also why the talent pipeline is treated as infrastructure. A first undergraduate major and a first doctoral program do not produce devices overnight, but they do reduce the chronic dependence on a handful of principal investigators. For a field where engineering, neuroscience, clinical medicine and regulatory science all meet, a steady graduate supply is what turns a headline lab into a durable industry.

## Honest limitations

Several strong claims — "world's largest patent pool," "internationally leading core metrics" — come from the lab and regional state-media accounts, not from an independent patent-count audit I could verify. Rehab efficacy for the Shengong devices rests on hospital clinical tests cited by the lab; I did not locate independently reviewed randomized trials for each product. Non-invasive BCI rehab is promising but evidence quality varies by device and by condition, and "medical-insurance coverage" details differ by region and product. Read the Tianjin story as an industrialization case study, not as proof that every device works equally well.

## What readers can do now

- Track the BCI undergraduate and doctoral programs as a signal of where China's neurotech talent is being concentrated over the next decade.

- For rehab seekers, ask the concrete questions that matter: does the device hold a medical-device registration (注册证), and is it reimbursable where you live? Marketing language is not a substitute.

- Watch the 1-billion-yuan fund's portfolio — the startups it backs will reveal which BCI sub-segments (chips, rehab, wearables) are actually commercializing.

---

Published by NeuroAI (https://neuroai.site/) — https://neuroai.site/a/na-brain-tianjin-haihe-lab-bci
Free to quote with attribution and a link to the original.
